Caliway Biopharmaceuticals Co Ltd

As of June 30, 2026, Caliway Biopharmaceuticals Co Ltd carries a market capitalization of 155.33B, placing it among publicly traded companies globally. Its enterprise value stands at 151.39B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Caliway Biopharmaceuticals Co Ltd's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Caliway Biopharmaceuticals Co Ltd has 1.56B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 5,298.88, and the price-to-book ratio stands at 16.87.

These figures are as of June 30, 2026. The EV/Sales ratio of 5,150.50 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 151.39B versus a market cap of 155.33B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Caliway Biopharmaceuticals Co Ltd maintains a current ratio of 60.03, meaning it holds 60.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.17, indicating moderate leverage, while an interest coverage ratio of -2,020.26 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Caliway Biopharmaceuticals Co Ltd posted a negative return on equity (ROE) of -2.77, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.72, reflecting losses generated across the asset base. The company generates approximately 716,902.44 in revenue per employee across its workforce of 41.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.42 indicates how many times Caliway Biopharmaceuticals Co Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Caliway Biopharmaceuticals Co Ltd's stock has declined approximately 55.14% over the past 52 weeks. The 50-day moving average sits at 88.03, while the 200-day moving average is 112.30.

Over the twelve months ended June 30, 2026, Caliway Biopharmaceuticals Co Ltd generated 29.39M in revenue and converted that into -257.81M in net income, yielding earnings per share of -0.17. EBITDA reached -800.02M, while operating income came in at -831.08M.

As of June 30, 2026, Caliway Biopharmaceuticals Co Ltd holds 4.05B in cash and equivalents against 107.95M in total debt, resulting in a net debt position of -3.05B. Total book value stands at 9.21B, with working capital of 4.13B providing operational flexibility.

Caliway Biopharmaceuticals Co Ltd produced -280.99M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -20.55M in capital expenditures, free cash flow totaled -301.54M - equivalent to -0.19 per share.

Over the twelve months ended June 30, 2026, Caliway Biopharmaceuticals Co Ltd posted a gross margin of 70.30, reflecting its pricing power and cost economics. The operating margin of -2,827.47 and net profit margin of -877.11 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.19: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.07, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Caliway Biopharmaceuticals Co Ltd shareholders.

Caliway Biopharmaceuticals Co Ltd's most recent stock split took place on July 21, 2025 with a 1:10 split ratio.

As of June 30, 2026, Caliway Biopharmaceuticals Co Ltd has an Altman Z-Score of 416.49, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.